特此公告。 登录新浪财经APP 搜索【信披】查看更多考评等级 根据《公开募集证券投资基金运作管理办法》、《公开募集证券投资基金信息披露管理办法》及相关法 律法规、各基金基金合同及招募说明书等规定，在履行规定审批程序并经基金托管人同意后，南方基金 管理股份有限公司（以下简称"本公司"）旗下部分公募基金参加了苏州天准科技股份有限公司（以下简 称"天准科技"或"发行人"）公开发行A股可转换公司债券的优先配售。天准科技本次可转换公司债券发 行的主承销商华泰联合证券有限责任公司为本公司股东控制的子公司，因此本次优先配售涉及关联交 易。 根据天准科技发布的《苏州天准科技股份有限公司向不特定对象发行可转换公司债券网上中签率及优先 配售结果公告》以及其他相关公告,现将本公司旗下公募基金参与天准科技本次发行优先配售相关信息 公告如下： 投资者可登陆本公司网站（www.nffund.com），或拨打客户服务电话400-889-8899咨询相关信息。 南方基金管理股份有限公司 2025年12月16日 ...

Core Viewpoint - The transaction involving the acquisition of 100% equity of Guangzhou Metro Engineering Consulting Co., Ltd. by the company through share issuance has been approved by the Shenzhen Stock Exchange's M&A Review Committee, pending final approval from the China Securities Regulatory Commission [1][2]. Group 1: Transaction Details - The company plans to purchase 100% equity of the target company from Guangzhou Metro Group for a total price of 51,110.00 million [1][2]. - The transaction is expected to enhance the company's asset value, with an assessed value of the target company at 51,110.00 million, reflecting an increase of 40,472.67 million and a growth rate of 380.48% [2]. Group 2: Fundraising and Financial Structure - The company aims to raise up to 12,777.50 million in supplementary funds, which will not exceed 100% of the transaction price [3]. - The raised funds will be used for working capital and debt repayment after deducting intermediary fees and taxes [3]. - The issuance of shares for fundraising will be directed towards no more than 35 specific investors, with the share price set at a minimum of 80% of the average trading price over the previous 20 trading days [3].

中国经济网北京12月11日讯 迪哲医药（688192.SH）近日发布2025年第三季度报告显示，2025年 第三季度，公司实现营业收入2.31亿元，同比增长71.46%；归属于上市公司股东的净利润-2.03亿元； 归属于上市公司股东的扣除非经常性损益的净利润-2.11亿元。 2025年前三季度，公司实现营业收入5.86亿元，同比增长73.23%；归属于上市公司股东的净利 润-5.80亿元；归属于上市公司股东的扣除非经常性损益的净利润-6.31亿元；经营活动产生的现金流量 净额为-4.24亿元。 | | | | | HATTA A SAMILA 年初至报告期 | | --- | --- | --- | --- | --- | | | | 本报告期比上 | | 末比上年同期 | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | | | | | 动幅度(%) | | 增减变动幅度 | | | | | | (%) | | 营业收入 | 231,299,714.08 | 71.46 | 586,301,134.90 | 73.23 | | 到海总额 | -203.910.752.21 | 不适用 | - ...

沐曦集成电路（上海）股份有限公司 首次公开发行股票并在科创板上市 发行结果公告 保荐人（主承销商）：华泰联合证券有限责任公司 特别提示 沐曦集成电路（上海）股份有限公司（以下简称"沐曦股份"、"发行人" 或"公司"）首次公开发行人民币普通股（A 股）并在科创板上市（以下简称"本 次发行"）的申请已经上海证券交易所（以下简称"上交所"）上市审核委员会 审议通过，并已经中国证券监督管理委员会同意注册（证监许可〔2025〕2507 号）。 本次发行的保荐人（主承销商）为华泰联合证券有限责任公司（以下简称"华 泰联合证券"、"保荐人（主承销商）"或"主承销商"）。发行人股票简称为 "沐曦股份"，扩位简称为"沐曦股份"，股票代码为"688802"。 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配售"）、 网下向符合条件的投资者询价配售（以下简称"网下发行"）与网上向持有上海 市场非限售 A 股股份和非限售存托凭证市值的社会公众投资者定价发行（以下 简称"网上发行"）相结合的方式进行。 发行人和保荐人（主承销商）根据初步询价结果，综合评估公司合理投资价 值、可比公司二级市场估值水平、所属行业二级市场估值水平 ...

Core Viewpoint - The announcement from China Securities Index Co., Ltd. regarding the periodic adjustment of various indices, including the CSI 300, CSI 500, and CSI 1000, indicates significant changes in sample stocks, effective after market close on December 12, 2025 [1]. Group 1: Index Adjustments - The CSI 300 index will replace 11 sample stocks, the CSI 500 will replace 50, the CSI 1000 will replace 100, the CSI A50 will replace 4, the CSI A100 will replace 6, and the CSI A500 will replace 20 [1]. - Notably, NuoVivian (688105.SH) has been removed from the CSI 1000 index sample [2]. Group 2: NuoVivian Financial Performance - In 2024, NuoVivian reported a revenue of 1.378 billion yuan, a year-on-year increase of 7.15%, but a net loss attributable to shareholders of 18.09 million yuan, compared to a loss of 70.96 million yuan in the previous year [3]. - For the first three quarters of 2025, NuoVivian achieved a revenue of 0.952 billion yuan, a year-on-year decrease of 3.40%, with a net profit of 6.62 million yuan, down 63.57% [4]. - The net cash flow from operating activities for NuoVivian was 64.55 million yuan in the first three quarters of 2025, compared to a negative cash flow of 99.99 million yuan in the same period last year [4]. Group 3: IPO and Fundraising - NuoVivian was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 15, 2021, with an issuance of 40.01 million shares at a price of 55.00 yuan per share, raising a total of 2.201 billion yuan [4]. - The net amount raised after deducting issuance costs was 2.109 billion yuan, exceeding the original plan by 907 million yuan [4]. - The total issuance costs amounted to 91.38 million yuan, with the lead underwriter, Huatai United Securities, receiving 72.64 million yuan in fees [4].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意天合光能股份有限公司向不特定对象发行可转换公司债券 注册的批复》（证监许可〔2023〕157号）同意注册，天合光能股份有限公司（以下简称"公司"）向不 特定对象发行可转债8,864,751手（8,864.751万张），每张面值为人民币100元，募集资金总额 8,864,751,000.00元，扣除发行费用48,650,279.85元（不含增值税）后，募集资金净额为8,816,100,720.15 元。上述募集资金已全部到位，经容诚会计师事务所（特殊普通合伙）验证，并于2023年2月17日出具 了容诚验字[2023] 200Z0002号验资报告。 上述募集资金到账后，公司对募集资金采用了专户存储制度，并与保荐人、存放募集资金的商业银行签 署了募集资金专户存储监管协议。 二、本次新增开设募集资金专项账户情况 2025年12月8日，公司召开第三届董事会第三十八次会议，审议通过《关于新增开立募集资金专户并签 订三方监管协议的议 ...

Group 1 - Dongxing Medical (301290.SZ) announced a share reduction plan by shareholder Jiang Shihua, who holds 5,070,000 shares (5.0612% of total shares) [1] - Jiang plans to reduce up to 986,806 shares (not exceeding 0.9851% of total shares) within two months from December 29, 2025, through centralized bidding or block trading [1] - The reduction will not change the company's control or affect its ongoing operations, as Jiang is not a controlling shareholder [1] Group 2 - Dongxing Medical raised a total of 1,104.16 million yuan in its IPO, with a net amount of 1,002.57 million yuan after deducting issuance costs [2] - The final net fundraising amount exceeded the original plan by 389.62 million yuan [2] - The funds are intended for projects including intelligent manufacturing of medical device components and the development of new minimally invasive surgical products [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、募集资金的基本情况 根据中国证券监督管理委员会出具的《关于同意成都智明达电子股份有限公司向特定对象发行股票注册 的批复》（证监许可〔2025〕2505号），成都智明达电子股份有限公司（以下简称"公司"）获准向特定 对象发行人民币普通股（A股）6,278,999股，每股面值为人民币1元，发行价格为人民币33.19元/股，募 集资金总额为人民币208,399,976.81元，扣除各项不含增值税发行费用为人民币3,000,094.42元，实际募 集资金净额为人民币205,399,882.39元。 截至2025年11月26日止，上述募集资金已全部到位，并经信永中和会计师事务所（特殊普通合伙）审 验，于2025年11月27日出具《验资报告》（XYZH2025BJAG1B0440）。 公司已根据相关规定将上述募集资金进行了专户存储管理，并与保荐机构华泰联合证券有限责任公司 （以下简称"华泰联合证券"）以及成都银行金河支行签署了募集资金三方监管协议。 二、本次募集资金专户存储三方监管协 ...

文/梧桐小编 12月5日，安徽证监局公布了对华泰联合证券、刘伟、于兆祥采取出具警示函措施的决定，对国元证券、杨少杰、刘民昊采取出具警示函措施的决定，对安徽天禾 律师事务所、洪雅娴、李洋、朱乐乐采取出具警示函措施的决定。 经查，华泰联合证券、国元证券作为2025年度安徽富煌钢构股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易项目的财务顾问，在接受委托 出具财务顾问专业意见过程中，未对标的公司合肥中科君达视界技术股份有限公司（以下简称"中科视界"）收入确认跨期问题保持充分的职业审慎、未充分核查 中科视界与部分经销类客户的交易实质，导致制作、出具的独立财务顾问报告存在不实记载。刘伟、于兆祥作为华泰联合证券项目主办人，杨少杰、刘民昊作为 国元证券项目主办人，对以上违规行为负有主要责任。安徽证监局决定对华泰联合证券及两名项目主办人、国元证券及两名项目主办人采取出具警示函的行政监 管措施，并记入证券期货市场诚信档案。 经查，安徽天禾律师事务所在为某股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易项目提供证券法律业务过程中存在以下问题：一是对标 的公司股权核查验证不充分，在未获取到相关个人流水的 ...

Core Viewpoint - The article discusses the regulatory actions taken against Guoyuan Securities and Huatai United Securities for their professional misconduct in a merger and acquisition project involving Anhui Fuhuang Steel Structure Co., Ltd. and Zhongke Vision Technology Co., Ltd. [2][5][6] Group 1: Regulatory Actions - The Anhui Securities Regulatory Bureau issued warning letters to both Guoyuan Securities and Huatai United Securities for their failures in the same merger and acquisition project [2][6]. - The two firms failed to exercise sufficient professional caution regarding revenue recognition issues and did not adequately verify the substance of transactions with certain clients, leading to inaccuracies in their independent financial advisory reports [6][5]. Group 2: Implications for Financial Advisors - The misconduct raises concerns about the responsibility division and collaborative effectiveness of multiple financial advisors in complex merger transactions [6]. - The article emphasizes the importance of financial advisors in ensuring the quality and efficiency of transactions, highlighting that failures in key verification processes may indicate deeper issues in compliance and independent verification [6]. Group 3: Enhancements in M&A Services - The regulatory environment for mergers and acquisitions is being optimized, with new measures introduced to enhance market vitality and resource allocation efficiency [8]. - The China Securities Regulatory Commission is seeking public opinion on a draft regulation aimed at standardizing M&A behaviors and clarifying the roles and independence of financial advisors [8]. Group 4: Specific Requirements for Independent Financial Advisors - The Shanghai Stock Exchange has outlined three key requirements for independent financial advisors: enhancing professional service capabilities, fulfilling due diligence responsibilities, and strengthening internal control mechanisms [9]. - Advisors are encouraged to improve their understanding of industries and transactions, conduct thorough investigations, and establish effective internal controls to ensure high-quality service delivery [9].